Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos Corporation (NYSE: GKOS) reported Q2 2022 net sales of $72.7 million, a decrease from $78.1 million in Q2 2021. Key segments included $56.1 million from glaucoma and $16.6 million from corneal health. Gross margin was approximately 75%, down from 77% year-over-year. Notably, R&D expenses surged 31% to $31.7 million. Glaukos raised its full-year revenue guidance to $275 million to $280 million, up from $270 million to $275 million. The company ended the quarter with approximately $400 million in cash and equivalents.
Glaukos Corporation (NYSE: GKOS) is scheduled to release its Q2 2022 financial results after the market closes on August 3, 2022. The management will hold a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast on the company's website. Glaukos focuses on innovative therapies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012.
Glaukos Corporation (NYSE: GKOS) announced its participation in the William Blair 42nd Annual Growth Stock Conference scheduled for June 8, 2022, at 8:40 a.m. CT in Chicago, IL. The event will feature a live and archived webcast available on the company's investor relations website. Glaukos focuses on innovative ophthalmic medical technologies targeting glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its first device launched in 2012. The company continues to advance treatment options in these areas through ongoing innovations.
Glaukos Corporation (NYSE: GKOS) announced its virtual participation in the Piper Sandler Ophthalmology Symposium on May 23, 2022, at 2:00 p.m. ET. The company is focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional treatments, launching its first MIGS device in 2012. The event will feature a live and archived webcast accessible through the Glaukos Investors section.
Glaukos Corporation (NYSE: GKOS) reported Q1 2022 financial results, with net sales of $67.7 million, slightly down from $68.0 million in Q1 2021. Glaucoma sales accounted for $51.5 million, while Corneal Health contributed $16.1 million. The gross margin was approximately 75%, and operating expenses increased to $40.8 million. The company reported a net income of $5.4 million ($0.11 per diluted share), compared to a net loss of $16.5 million in the same period last year. Glaukos updated its 2022 net sales guidance to $270 million - $275 million.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present its innovative products at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 22-26, 2022, in Washington, D.C. Glaukos is sponsoring an educational symposium titled “Expanding Your Treatment Algorithm: New, Innovative Product Portfolio from Glaukos” on April 22 at 5:30 PM, featuring notable experts. Key presentations will include findings on the Trabecular Micro-Bypass Stent and other advancements in glaucoma and corneal health therapies, enhancing their market presence and potential future growth.
Summary not available.
Glaukos Corporation (NYSE: GKOS) will announce its first quarter 2022 financial results after market close on May 4, 2022. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the findings. Investors can access the live webcast through the company's website and call in using specific phone numbers for U.S. and international participants. Glaukos specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, having introduced Micro-Invasive Glaucoma Surgery (MIGS) in 2012.
Glaukos Corporation (NYSE: GKOS) has announced the initiation of a Phase 2 clinical program for its third-generation iLink™ therapy aimed at treating keratoconus. This innovative therapy utilizes a proprietary system to deliver ultraviolet light for corneal cross-linking, enhancing the strength and shape of the cornea. The Phase 2 study will involve two multi-center, randomized, controlled trials to assess customized versus non-customized treatment patterns and a new bio-activation system. Patient enrollment will occur across the United States, Europe, South America, and Asia, with a follow-up period of six months.
Glaukos Corporation (GKOS) reported its Q4 2021 net sales at $73.2 million, consistent with Q4 2020. Glaucoma and Corneal Health net sales were $57.1 million and $16.2 million, respectively. The gross margin improved to 77% from 73% a year earlier. However, the company faced a net loss of $21.9 million, or ($0.47) per diluted share, worsened from a net loss of $10.6 million in Q4 2020. For the full year, net sales increased by 31% to $294.0 million. The company projects 2022 net sales between $265 million and $275 million.